Related Experiment Video
Updated: Nov 21, 2025
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Downregulation of FHOD1 Inhibits Metastatic Potential in A549 Cells
Marta Hałas-Wiśniewska1, Magdalena Izdebska1, Wioletta Zielińska1
1Department of Histology and Embryology, Nicolaus Copernicus University in Toruń, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Bydgoszcz 85-092, Poland.
Purpose:
Metastasis remains a serious clinical problem in which epithelial-to-mesenchymal transition is strictly involved. The change of cell phenotype is closely related to the dynamics of the cytoskeleton. Regarding the great interest in microfilaments, the manipulation of ABPs (actin-binding proteins) appears to be an interesting treatment strategy.
Material:
The research material was the highly aggressive A549 cells with FHOD1 (F FH1/FH2 domain-containing protein 1) downregulation. The metastatic potential of the cells and the sensitivity to treatment with alkaloids (piperlongumine, sanguinarine) were analyzed.
Results:
In comparison to A549 cells with naïve expression of FHOD1, those after manipulation were characterized by a reduced migratory potential. The obtained results were associated with microfilaments and vimentin reorganization induced by the manipulation of FHOD1 together with alkaloids treatment. The result was also an increase in the percentage of late apoptotic cells.
Conclusion:
Downregulation of FHOD1 induced reorganization of microfilament network followed by the reduction in the metastatic potential of the A549 cells, as well as their sensitization to selected compounds. The presented results and the analysis of clinical data indicate the possibility of transferring research from the basic level to in vivo models in the context of manipulation of ABPs as a new therapeutic target in oncology.
Insights
Downregulating FHOD1 in cancer cells reduced their metastatic potential and increased sensitivity to alkaloids. This suggests targeting actin-binding proteins (ABPs) could be a novel oncology treatment strategy.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Metastasis, a critical clinical challenge, involves epithelial-to-mesenchymal transition, which is linked to cytoskeleton dynamics.
- Actin-binding proteins (ABPs) play a crucial role in regulating the cytoskeleton and cell phenotype.
- Targeting ABPs presents a potential therapeutic strategy for managing metastatic cancer.
Purpose of the Study:
- To investigate the effect of FHOD1 (FH1/FH2 domain-containing protein 1) downregulation on the metastatic potential of A549 lung cancer cells.
- To analyze the sensitivity of FHOD1-manipulated cells to alkaloid treatments (piperlongumine, sanguinarine).
- To explore the role of microfilament reorganization in FHOD1-mediated effects on cell metastasis.
Main Methods:
- Utilized A549 cells with downregulated FHOD1 expression.
- Assessed cellular metastatic potential and sensitivity to piperlongumine and sanguinarine.
- Analyzed microfilament and vimentin reorganization using microscopy.
- Quantified late apoptotic cells to evaluate treatment efficacy.
Main Results:
- FHOD1 downregulation significantly reduced the migratory potential of A549 cells.
- Alkaloid treatment, combined with FHOD1 manipulation, induced microfilament and vimentin reorganization.
- A notable increase in late apoptotic cells was observed following FHOD1 downregulation and alkaloid treatment.
- The study observed a correlation between FHOD1 levels, cytoskeletal dynamics, and metastatic behavior.
Conclusions:
- FHOD1 downregulation reorganizes the microfilament network, decreasing metastatic potential and enhancing A549 cell sensitivity to specific compounds.
- These findings highlight the potential of targeting ABPs, like FHOD1, as a therapeutic strategy in oncology.
- The results support the translation of basic research on ABPs to in vivo models for cancer treatment development.
